|
ES2160949T3
(es)
*
|
1996-03-29 |
2001-11-16 |
Searle & Co |
Derivados de fenilen-sulfonamida sustituidos en meta.
|
|
GB9805655D0
(en)
|
1998-03-16 |
1998-05-13 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
US6521626B1
(en)
|
1998-03-24 |
2003-02-18 |
Celltech R&D Limited |
Thiocarboxamide derivatives
|
|
JP4064059B2
(ja)
|
1998-04-09 |
2008-03-19 |
明治製菓株式会社 |
インテグリンαＶβ３拮抗剤としてのアミノピペリジン誘導体
|
|
GB9814414D0
(en)
|
1998-07-03 |
1998-09-02 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
AU747784B2
(en)
*
|
1998-07-29 |
2002-05-23 |
Merck & Co., Inc. |
Integrin receptor antagonists
|
|
GB9821061D0
(en)
|
1998-09-28 |
1998-11-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
GB9826174D0
(en)
|
1998-11-30 |
1999-01-20 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
IL143901A0
(en)
|
1998-12-23 |
2002-04-21 |
Searle & Co |
Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
|
|
US6291503B1
(en)
|
1999-01-15 |
2001-09-18 |
Bayer Aktiengesellschaft |
β-phenylalanine derivatives as integrin antagonists
|
|
US6518283B1
(en)
|
1999-05-28 |
2003-02-11 |
Celltech R&D Limited |
Squaric acid derivatives
|
|
US6750219B1
(en)
|
1999-08-05 |
2004-06-15 |
Meiji Seika Kaisha, Ltd. |
Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity
|
|
CA2383086A1
(en)
*
|
1999-09-08 |
2001-03-15 |
Joseph P. Steiner |
Non-peptidic cyclophilin binding compounds and their use
|
|
EP1088821A1
(en)
*
|
1999-09-28 |
2001-04-04 |
Applied Research Systems ARS Holding N.V. |
Pharmaceutically active sulfonamide derivatives
|
|
US6534513B1
(en)
|
1999-09-29 |
2003-03-18 |
Celltech R&D Limited |
Phenylalkanoic acid derivatives
|
|
AU781747B2
(en)
*
|
1999-10-08 |
2005-06-09 |
Meiji Seika Kaisha Ltd. |
3-aminopiperidine derivatives as integrin alphavbeta3 antagonists
|
|
US20050059669A1
(en)
*
|
1999-10-08 |
2005-03-17 |
Keiichi Ajito |
M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity
|
|
US6849639B2
(en)
|
1999-12-14 |
2005-02-01 |
Amgen Inc. |
Integrin inhibitors and their methods of use
|
|
US6455539B2
(en)
|
1999-12-23 |
2002-09-24 |
Celltech R&D Limited |
Squaric acid derivates
|
|
RU2240826C2
(ru)
|
2000-02-03 |
2004-11-27 |
Эйсай Ко., Лтд. |
Ингибитор экспрессии интегрина
|
|
JP2003531141A
(ja)
|
2000-04-17 |
2003-10-21 |
セルテック アール アンド ディ リミテッド |
エナミン誘導体
|
|
US6403608B1
(en)
|
2000-05-30 |
2002-06-11 |
Celltech R&D, Ltd. |
3-Substituted isoquinolin-1-yl derivatives
|
|
US6545013B2
(en)
|
2000-05-30 |
2003-04-08 |
Celltech R&D Limited |
2,7-naphthyridine derivatives
|
|
WO2002004426A1
(en)
|
2000-07-07 |
2002-01-17 |
Celltech R & D Limited |
Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
|
|
JP2004505110A
(ja)
|
2000-08-02 |
2004-02-19 |
セルテック アール アンド ディ リミテッド |
３位置換イソキノリン−１−イル誘導体
|
|
CA2435829A1
(en)
|
2001-01-25 |
2002-08-01 |
Guilford Pharmaceuticals Inc. |
Trisubstituted carbocyclic cyclophilin binding compounds and their use
|
|
ES2280502T3
(es)
*
|
2001-02-21 |
2007-09-16 |
EISAI R&D MANAGEMENT CO., LTD. |
Metodo para evaluar el efecto de un inhibidor de la angiogenesis a traves de la inhibicion de la expresion de integrinas.
|
|
US6710061B2
(en)
*
|
2001-03-09 |
2004-03-23 |
Ortho-Mcneil Pharamceutical, Inc. |
Aminopyrrolidine sulfonamides as serine protease inhibitors
|
|
GB0127615D0
(en)
*
|
2001-07-09 |
2002-01-09 |
Aventis Pharm Prod Inc |
Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity
|
|
CA2464472C
(en)
|
2001-10-22 |
2014-01-07 |
The Scripps Research Institute |
Antibody targeting compounds
|
|
WO2003059872A1
(en)
*
|
2001-12-31 |
2003-07-24 |
Bayer Pharmaceuticals Corporation |
Avb3 and avb5 integrin antagonists and methods of treating diseases or conditions associated with avb3 and avb5 integrins
|
|
JP2005533001A
(ja)
*
|
2002-03-04 |
2005-11-04 |
メディミューン，インコーポレーテッド |
インテグリンαｖβ３アンタゴニストを他の物質と併用投与する癌の予防または治療方法
|
|
JP2005525368A
(ja)
*
|
2002-03-04 |
2005-08-25 |
メディミューン，インコーポレーテッド |
インテグリンαｖβ３アンタゴニストをＨＭＧ−ＣｏＡ還元酵素阻害剤またはビスフォスフォネートと併用投与する障害の予防または治療方法
|
|
WO2004066956A2
(en)
*
|
2003-01-30 |
2004-08-12 |
Medimmune, Inc. |
Uses of integrin alphavbeta3 antagonists
|
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
|
US9296697B2
(en)
|
2005-08-24 |
2016-03-29 |
Abbott Laboratories |
Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors
|
|
EP1945262A2
(en)
*
|
2005-10-20 |
2008-07-23 |
The Scripps Research Institute |
Fc labeling for immunostaining and immunotargeting
|
|
ES2413504T3
(es)
|
2007-12-21 |
2013-07-16 |
Ligand Pharmaceuticals Inc. |
Moduladores selectivos del receptor de andrógeno (SARM) y usos de los mismos
|
|
WO2010093706A2
(en)
|
2009-02-10 |
2010-08-19 |
The Scripps Research Institute |
Chemically programmed vaccination
|
|
WO2015181676A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Carbonitrile derivatives as selective androgen receptor modulators
|
|
BR112021020864A2
(pt)
|
2019-04-19 |
2021-12-14 |
Ligand Pharm Inc |
Formas cristalinas e métodos de produção de formas cristalinas de um composto
|
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|